Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonelokimab in Active Psoriatic Arthritis
NCT05640245Phase 2Completed
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Dec 2022
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH)
- Countries
- 8
01
Overview
A Phase 2 trial of sonelokimab in psoriatic arthritis (PsA), sponsored by MoonLake Immunotherapeutics. Started Dec 2022; status: completed.
02
Drugs
sonelokimab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05640245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05640245.